3188 results for «629»

Filter By

3188 results

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

20 May 2025 – From EuroPCR 2025

Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

Hostile access for TAVI procedure

21 May 2025 – From EuroPCR 2025

This session addresses the challenges of hostile vascular access in TAVI procedures. Learn to identify difficult access sites through pre-operative imaging, explore alternative approaches such as axillary access, techniques to overcome iliac access difficulties, and management of peri- and post-operative complications by vascular surgeons.

Hostile access for TAVI procedure

Align for the future with next gen Myval transcatheter heart valve series

16 Nov 2025 – From PCR London Valves 2025

Discover how the latest Myval transcatheter heart valve (THV) innovations are shaping TAVI outcomes. This PCR London Valves 2025 session highlights the clinical evidence behind the next-gen Myval THV series, best practices for implantation, and upcoming innovations set to improve patient care. Learn step-by-step techniques for deploying Myval...

Align for the future with next gen Myval transcatheter heart valve series

Advancing structural heart with 3D ICE and device guidance

17 Nov 2025 – From PCR London Valves 2025

This PCR London Valves 2025 session explores how 3D TEE, 3D intracardiac echocardiography (ICE), and DeviceGuide technology sharpen procedural accuracy, strengthen operator confidence, and streamline decision-making in real time.

You’ll see how clearly defined team roles enhance both safety and efficiency, and how thoughtful workflow integration can reduce...

Advancing structural heart with 3D ICE and device guidance

A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment

18 Nov 2025 – From PCR London Valves 2025

This session examines the evolving treatment landscape for aortic regurgitation (AR) in light of new ESC guidelines and dedicated devices such as the JenaValve Trilogy System. It provides an in-depth look at refined diagnosis, optimized treatment strategies, and presents real-world data and clinical cases that highlight...

A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment

Cardiovalve hits the TARGET: advancing transcatheter valve replacement

18 Nov 2025 – From PCR London Valves 2025

This session highlights the features and procedural steps of the next-generation Cardiovalve systems for tricuspid and mitral valve replacement. It reviews interim results from the TARGET study, emphasizing echocardiographic findings and reverse remodeling effects, and discusses best practices for patient selection and the learning pathway to...

Cardiovalve hits the TARGET: advancing transcatheter valve replacement

Primary and secondary outcomes of the Women's Ischemia Trial to reduce events in non-obstructive coronary artery disease (WARRIOR)

31 Mar 2025

Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.

The manuscript for this trial has not been published and all assumptions are based upon the presentation.

Nicola Ryan

Author

Nicola Ryan
Primary and secondary outcomes of the Women's Ischemia Trial to reduce events in non-obstructive coronary artery disease

Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial

20 Sep 2022

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Nicola Ryan

Author

Nicola Ryan
10-Year Outcomes of Multicenter Randomized Controlled BEST Trial: Everolimus-Eluting Stents or Bypass Surgery for Mutivessel CAD
Didn’t find what you were looking for?